Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03148691
Other study ID # A-101-SEBK-204
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 17, 2017
Est. completion date April 3, 2018

Study information

Verified date May 2019
Source Aclaris Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the safety and effectiveness of 2 concentrations of A-101 compared to Vehicle for the treatment of 4 seborrheic keratosis (SK) Target Lesions on the trunk, extremities and face.


Description:

The primary objective of this study is to evaluate the safety and effectiveness of 2 concentrations of A-101 compared to Vehicle for the treatment of 4 seborrheic keratosis (SK) Target Lesions on the trunk, extremities and face.

The secondary objectives of this study include duration of response of A-101. During the study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face. For each subject, at least 1 SK Target Lesion must be on the face and at least 1 Target Lesion must be on the trunk or extremities. The Target Lesions will be treated at a maximum of two treatment visits.


Recruitment information / eligibility

Status Completed
Enrollment 253
Est. completion date April 3, 2018
Est. primary completion date February 28, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subject is able to comprehend and is willing to sign an informed consent for participation in this study.

2. Male or female = 18 years old.

3. Subject has a clinical diagnosis of stable clinically typical seborrheic keratosis.

4. Subject has 4 appropriate seborrheic keratosis Target Lesions on the trunk, extremities and face, with at least 1 Target Lesion on the face and at least 1 Target Lesion on the trunk or extremities. The 4 identified Target Lesions must meet the requirements as defined below:

1. Have a clinically typical appearance

2. Have a Physician's Lesion Assessment of = 2

3. Length that is = 5mm and = 15mm

4. Width that is = 5mm and = 15 mm

5. Thickness that is = 2mm

6. Be a discrete lesion

7. Be the only SK lesion present when centered in the area outlined by the provided circular template

8. Not be covered with hair which, the in the investigator's opinion, would interfere with the study medication treatment or the study evaluations

9. Not be in the intertriginous fold

10. Not be on the eyelids

11. Not be within 5mm of the orbital rim

12. Not be pedunculated

5. Subject chemistry and complete blood count results are within normal limits. If any of the laboratory values are outside normal range, the treating investigator must assess the value/s as NOT clinically significant and document this in the subject's medical chart in order for the subject to be eligible for randomization.

6. Woman of childbearing potential must have a negative urine pregnancy test within 14 days of the first application of study drug and agree to use an active method of birth control for the duration of the study.

7. Subject is non-pregnant and non-lactating.

8. Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of any Target Lesion or which exposes the subject to an unacceptable risk by study participation.

9. Subject is willing and able to follow all study instructions and to attend all study visits.

Exclusion Criteria:

1. Subject has clinically atypical and /or rapidly growing seborrheic keratosis lesions.

2. Subject has presence of multiple eruptive seborrheic keratosis lesions (Sign of Leser - Trelat).

3. Subject has current systemic malignancy.

4. Subject has used any of the following systemic therapies within the specified period prior to Visit 1:

- Retinoids; 180 days

- Corticosteroids; 28 days

- Anti-metabolites (e.g., methotrexate); 28 days

5. Subject has used any of the following topical therapies within the specified period prior to Visit 1 on, or in a proximity to any Target Lesion, that in the investigator's opinion interferes with the study medication treatment or the study assessments:

- LASER, light or other energy based therapy (e.g., intense pulsed light, photo-dynamic therapy; 180 days

- Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-Fluorouracil, or ingenol mebutate; 60 days

- Hydrogen peroxide: 90 days

- Retinoids; 28 days

- Microdermabrasion or superficial chemical peels; 14 days

- Corticosteroids or antibiotics; 14 days

6. Subject would require the use of any topical treatment (e.g. moisturizers, sunscreen) to any of the Target Lesions 12 hours prior to any study visit.

7. Subject currently has or has had any of the following within the specified period prior to Visit 1 on or in a proximity to any Target Lesion that, in the investigator's opinion, interferes with the study medication treatment or the study assessments:

- Cutaneous malignancy; 180 days

- Sunburn; currently

- Pre-malignancy (e.g. actinic keratosis); currently

- Body art (e.g. tattoos, piercing, etc.); currently

- Excessive tan; currently. The use of self-tanning lotions/sprays are prohibited.

8. Subject has a history of sensitivity to any of the ingredients in the study medications.

9. Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations.

10. Participation in another therapeutic investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to Visit 1.

Study Design


Intervention

Drug:
A-101
Topical Solution

Locations

Country Name City State
United States DermResearch Inc Austin Texas
United States Philadelphia Institute - Dermatology Fort Washington Pennsylvania
United States Greenville Dermatology Greenville South Carolina
United States The Skin Wellness Center, PC Clinical Research Division Knoxville Tennessee
United States Baumann Research Institute Miami Florida
United States Union Square Laser Dermatology New York New York
United States MedaPhase, Inc Newnan Georgia
United States Perelman Center for Advanced Medicine Philadelphia Pennsylvania
United States Center for Dermatology and Dermatologic Surgery Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Aclaris Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean of Per Subject Percentages of Target Lesions Judged to be Clear (PWA=0) at Visit 8 Mean of per subject percentages of target lesions judged to be clear (PWA=0) at Visit 8
Grade Descriptor
0 Clear: no visible seborrheic keratosis lesion
Near Clear: a visible seborrheic keratosis lesion with a surface appearance different from the surrounding skin (not elevated)
Thin: a visible seborrheic keratosis lesion (thickness = 1 mm)
Thick: a visible seborrheic keratosis lesion (thickness > 1 mm)
Day 106
See also
  Status Clinical Trial Phase
Completed NCT04229277 - Fast Track Diagnosis of Skin Cancer by Advanced Imaging N/A
Completed NCT02260180 - Study of A-101 for the Treatment of Seborrheic Keratosis Phase 2
Completed NCT01214564 - Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis Phase 2
Active, not recruiting NCT05136144 - Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis Phase 2
Recruiting NCT06108024 - A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis Phase 2
Completed NCT06046144 - Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors
Completed NCT03846531 - Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study N/A
Completed NCT03487588 - An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses Phase 4
Completed NCT02160626 - Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis Phase 2
Completed NCT00540566 - Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Completed NCT01159860 - Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses? N/A
Terminated NCT04688749 - Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
Completed NCT02667236 - A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. Phase 3
Completed NCT02667288 - An Open-Label Safety Study of A-101 Solution Phase 3
Completed NCT02667275 - A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis Phase 3
Completed NCT05353374 - Effectiveness of Sodium Fusidate Ointment Compared to Petrolatum for Wound Healing Following Cauterization N/A
Terminated NCT04249115 - Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study N/A